45%
of 2035 population
of 2035 population
Treatment options are limited and remain primarily symptomatic
Cardiovascular Disease
Cardiovascular disease remains the largest cause of mortality and healthcare costs, yet most therapies only address risk factors or disease symptoms, rather than improving heart function.
US Prevalence
Burden
1 in 3
deaths
deaths
Heart failure alone affects more than 64 million people worldwide
Precision Cardiology is Emerging
New genetic and functional insights are enabling precision therapies that can address disease drivers and improve patient heart function
Past
Drugging Risk Factors
Future
Drugging Heart Function
However, so far there is a lack of well-characterized precision drug targets that have been genetically and functionally validated in humans.
